Table 3.
Nanobodies in cancer clinical trials.
| Nanobody | Disease | Target | Clinical trial | Phase | Status | Ref. |
|---|---|---|---|---|---|---|
| 68GaNOTA-Anti-HER2 VHH1 | Breast carcinoma | HER2 | I | Completed | (17) | |
| 68GaNOTA-Anti-HER2 VHH1 | Metastatic breast carcinoma Locally advanced breast cancer |
HER2 | NCT03924466 | II | Recruiting | |
| 68GaNOTA-Anti-HER2 VHH1 | Breast neoplasm Breast carcinoma Receptor, ErbB-2 |
HER2 | NCT03331601 | II | Recruiting | |
| 99mTc-NM-02 | Breast cancer | HER2 | NCT04040686 | I | Recruiting | |
| 131I-SGMIB-Anti-HER2 VHH1 | Breast cancer Healthy volunteers |
HER2 | NCT02683083 | I | Completed | |
| 68GaNOTA-Anti-MMR VHH2 | Malignant solid tumor Breast cancer Head and neck cancer Melanoma (Skin) |
MMR | NCT04168528 | I/IIa | Recruiting | |
| 99mTc-Anti-PD-L1 | Non-small cell lung cancer | PD-L1 | NCT02978196 | I | Completed | (38) |
| L-DOS47 + Doxorubicin | Pancreas cancer | CEACAM6 | NCT04203641 | Ib/II | Recruiting | |
| L-DOS47 + Cisplatin/Vinorelbine | Lung adenocarcinoma | NCT03891173 | II | Recruiting | ||
| KN035 + Trastuzumab/Docetaxel | HER2 + Breast cancer | PD-L1 | NCT04034823 | II | Not yet recruiting | |
| KN035 | Advanced/Metastatic solid tumors | PD-L1 | NCT03248843 | I | Unknown | |
| KN035 | Solid tumors Hepatocellular carcinoma |
PD-L1 | NCT03101488 | I | Unknown | |
| KN044 | Advanced solid tumors | CTLA-4 | NCT04126590 | I | Recruiting | |
| TC-210 T Cells | Mesothelioma Malignant/Pleura/Pleural/Peritoneum Mesothelioma Cholangiocarcinoma Recurrent cholangiocarcinoma Ovarian cancer Non-small cell lung cancer |
Mesothelin | NCT03907852 | I/II | Recruiting | |
| CD19/CD20 bispecific CAR T cells | Refractory/Relapsed B-cell lymphoma stage | CD19/CD20 | NCT03881761 | I | Recruiting | |
| BCMA CAR T cells | Refractory/Relapsed myeloma | BCMA | NCT03664661 | I | Recruiting | |
| Anti-idiotypic | Multiple myeloma | Paraproteins | NCT03956615 | N/A (Feasibility) | Recruiting | |
| TAS266 | Advanced solid tumors | DR5 | NCT01529307 | I | Terminated | (12) |
HER2, human epidermal growth factor receptor-2; MMR, macrophage mannose receptor; PD-L1, programmed death ligand 1; CTLA-4, cytotoxic T lymphocyte antigen-4; CEACAM6, carcinoembryonic antigen cell adhesion molecule-6; CD19/CD20, cluster of differentiation 19/20; BCMA, B-cell maturation antigen; DR5, death receptor-5.